BusinessBeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in ChinaBy Nasdaq OMXFeb 27, 2018, 11:00 PM UTC
BusinessBeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 5:15 PM UTC
BusinessBeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 2:00 PM UTC
